Carcinoma de pulmón no microcítico

  1. López, A. 1
  2. Escalera, E. 1
  3. Del Barco, E. 1
  4. Bellido, L. 1
  5. Cigarral, B. 1
  6. Barrios, B. 1
  7. Casado, D. 1
  8. Claros, J. 1
  9. Figuero, L. 1
  10. Olivares, A. 1
  11. Terán, E. 1
  12. Cruz, J.J. 1
  1. 1 Instituto de Investigación Biomédica de Salamanca (IBSAL), Servicio de Oncología Médica, Complejo Asistencial Universitario de Salamanca (CAUSA), Salamanca, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades oncológicas (II)Tumores torácicos. Cáncer de cabeza y cuello

Serie: 13

Número: 25

Páginas: 1377-1387

Tipo: Artículo

DOI: 10.1016/J.MED.2021.02.002 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

Las neoplasias pulmonares son la primera causa de muerte por cáncer en el mundo. La incidencia y la mortalidad de esta enfermedad se correlacionan estrechamente con su principal factor etiológico, el tabaco. El adenocarcinoma es el subtipo histológico diagnosticado con más frecuencia, seguido del carcinoma epidermoide, el carcinoma de células grandes y el carcinoma microcítico de pulmón, que se engloba dentro de los carcinomas neuroendocrinos. Debido a los avances realizados en la investigación de terapias diana en los últimos años, resulta de gran importancia el estudio de puntos de control inmunitario y de mutaciones oncogénicas específicas que pueden modificar la actitud terapéutica del tumor, especialmente en las variantes de adenocarcinoma. Llevar a cabo una adecuada estadificación de la enfermedad, así como el diagnóstico molecular, resulta de vital importancia para valorar el pronóstico y adoptar la actitud terapéutica adecuada.

Referencias bibliográficas

  • IARC. Cancer incidence, mortality and prevalence worldwide GLOBO-CAN 2012. Disponible en: http://gco.iarc.fr/✔2. Cifras del cáncer en España. SEOM 2020. Disponible en: https://seom.org/seomcms/images/stories/recursos/Cifras_del_cancer_2020.pdf
  • Jemal A, Ma J, Rosenberg PS, Siegel R, Anderson WF. Increasing lung cancer death rates among young women in southern and midwestern States. J Clin Oncol. 2012;30:2739-44.
  • Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. Eur Respir J. 2016;48:889-902.
  • Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol. 2006;24:2245-51.
  • Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO classification of tumours of the lung, pleura, thymus and heart. 4ª ed. Lyon, France: IARC Press; 2015.
  • Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol. 2018;36:911-9.
  • Mok T, Carbone D, Hirsch F. IASLC Atlas of EGFR testing in Lung cancer. IASLC 2017. Disponible en: http://wclc2017.iaslc.org/.
  • Tsao M, Hirsch F, Yatabe Y. IASLC Atlas of ALK and ROS1 Testing in Lung Cancer. 2ª ed. Aurora, CO: International Association for the Study of Lung Cancer 2016.
  • Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-50.
  • Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer. 3ª ed. American Col-lege of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143: e142S–e165S.
  • Takada K, Toyokawa G, Shoji F, Okamoto T, Maehara Y. The significance of the pd-l1 expression in non-small-cell lung cancer: trenchant double swords as predictive and prognostic markers. Clin Lung Cancer. 2018; 19(2):120-9.
  • Brierley J, Gospodarowicz MK, Wittekind CH, eds. TNM classi-fication of malignant tumours. 8ª ed. Oxford, UK; Hoboken, NJ: John Wiley & Sons, Inc.; 2017.
  • Woodard GA, Jones KD, Jablons DM. Lung cancer staging and progno-sis. Cancer Treat Res. 2016;170:47-75.
  • Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Ste-phens RJ, et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-9.
  • Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, et al. Non‐Small Cell Lung Cancer Collaborative Group. Adjuvant chemo-therapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev. 2015;(3):CD011430.
  • Herbst R, Tsuboi M, John T, Grohé C, Majem M, Goldman JW, et al. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. J Clin Oncol. 2020;38Suppl18:LBA5-LBA5.
  • Le Pechoux C, Pourel N, Barlesi F, Riesterer O, Lavole L, Bardet A. An international randomized trial, comparing post-operative con-formal radiotherapy (PORT) to no PORT, in patients with com-pletely resected non-small cell lung cancer (NSCLC) and mediasti-nal N2 involvement: Primary end-point analysis of Lung ART (IFCT-0503, UK NCRI, SAKK) NCT00410683. Ann Oncol. 2020; 31Suppl4:S1178.
  • Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, et al. Neoadjuvant chemotherapy and nivolumab in re-sectable non-small-cell lung cancer (NADIM): an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2020 Nov;21(11): 1413-22.
  • Pentheroudakis G; ESMO Guidelines Committee. Recent eUp-date to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2020; 31(9):1265-6.
  • Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. PACIFIC Investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018; 379(24):2342-50.
  • Faivre-Finn C, Vicente D, Kurate T, Planchard D, Paz-Ares L, Vansteenkiste JF, et al. Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PA-CIFIC trial. ESMO. 2020;19:LBA49.
  • Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Itali-ana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multi-centre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46.
  • Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013;105(9):595-605.
  • Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018; 378:113-25.
  • Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalin-gam SS, et al; AURA3 Investigators. Osimertinib or platinum-peme-trexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017; 376(7):629-40.
  • Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167-77.
  • Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390:29-39.
  • Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-posi-tive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056-64.
  • Besse B, Solomon BJ, Felip E, Bauer TM, Ou SI, Soo RA, et al. Lorlatinib in patients (pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): updated efficacy and safety. J Clin Oncol. 2018; 36Suppl15:9032.
  • Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963-71.
  • Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Hel-land Å, et al. Dabrafenib plus trametinib in patients with previ-ously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18: 1307-16.
  • Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizum-ab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-33.
  • Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078-92.
  • Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Noga-mi N, Rodríguez-Abreu D, et al. Atezolizumab for first-line treatment of metastatic non-squamous NSCLC. N Engl J Med. 2018;378:2288-301.
  • Paz-Ares LG, Luft A, Vicente D, et al. Pembrolizumab plus che-motherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379:2040-51.
  • Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clin-ical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
  • NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of in-dividual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617-25.
  • Non-Small Cell Lung Cancer Collaborative Group. Chemother-apy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2010; CD007309.
  • Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gem-citabine with cisplatin plus pemetrexed in chemotherapy-naive pa-tients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-51.
  • Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histol-ogy: a review of two phase III studies. Oncologist. 2009;14:253-63.
  • Lima AB, Macedo LT, Sasse AD. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2011;6:e22681.
  • Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24:20-30.
  • Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Pod-dubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-35.
  • Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-39.
  • Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previ-ously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-65.
  • Herbst R, Garon E, Kim D-W, et al. OA03.07 KEYNOTE-010: durable clinical benefit in patients with previously treated, PD-L1-expressing NSCLC who completed pembrolizumab. J Thoracic On-col. 2017;12:S254-5.
  • Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based che-motherapy. J Clin Oncol. 2000;18:2095-103.
  • Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-97.
Fuente de los datos: Dialnet